Point72 Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Point72 Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$685K	Sell	31,938 -124,268	-80%	-$1.75M	﹤0.01%	2977
2025 Q4	$1.46M	Buy	+156,206	New	+$1.3M	﹤0.01%	2663
2025 Q3	–	Sell	-391,280	Closed	-$2.54M	–	2386
2025 Q2	$2.54M	Buy	+391,280	New	+$2.69M	0.01%	1201
2024 Q3	–	Sell	-470,247	Closed	-$6.48M	–	2055
2024 Q2	$6.48M	Buy	+470,247	New	+$6.88M	0.02%	768
2024 Q1	–	Sell	-88,000	Closed	-$1.28M	–	2274
2023 Q4	$1.28M	Sell	88,000 -456,560	-84%	-$5.53M	﹤0.01%	1329
2023 Q3	$6.68M	Buy	544,560 +413,560	+316%	+$5.39M	0.02%	791
2023 Q2	$1.56M	Buy	+131,000	New	+$1.71M	﹤0.01%	1078
2023 Q1	–	Sell	-461,631	Closed	-$9.93M	–	2294
2022 Q4	$9.93M	Buy	+461,631	New	+$9.47M	0.03%	554

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Point72 Asset Management's DAWN Position: Q1 2026 in Review

Point72 Asset Management reduced its Day One Biopharmaceuticals (DAWN) stake by 80% in Q1 2026, selling an estimated $1.75M and leaving 31,938 shares worth $685K. The position accounts for ﹤0.01% of the portfolio, ranked #2977.

Point72 Asset Management first reported a position in DAWN in Q4 2022 and has held it in 8 quarters since. The position peaked at $9.93M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Point72 Asset Management held 31,938 shares of Day One Biopharmaceuticals worth $685K as of Q1 2026.
Point72 Asset Management sold 124,268 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.75M.
Day One Biopharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2977 holding.
Point72 Asset Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Point72 Asset Management's Day One Biopharmaceuticals position peaked at $9.93M in Q4 2022.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.